An interventional study of Whole blood for ctDNA in Germ Cell Cancer Metastatic, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Indiana University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States — 25 open to participants now, 36 under way, 3 of them phase 3. Neoplasms, Germ Cell and Embryonal · United States.
Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, this one is the 12th largest by planned enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 with no phase, reaches primary completion later than 33 of the 35 other live ones, and was the 91st registered.
167 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 49 are open to participants now.
Browse Neoplasms, Germ Cell and Embryonal studies →25 of the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
University of California, Irvine · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 3–21
Indiana University · Sites in United States
Ages 18+
Zymeworks BC Inc. · Sites in United States, Ireland, Japan and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Neoplasms, Germ Cell and Embryonal studies recruiting now, 20 (50%) set no upper age limit and 16 (40%) stop at 75 or younger; 22 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 39 · Phase 3 4
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 36 across 124 interventional studies indexed under Neoplasms, Germ Cell and Embryonal.
Median enrollment 36 across the 81 interventional studies, 213 across the 13 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 94 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 4 studies filed under Neoplasms, Germ Cell and Embryonal — fewer than ten, so there is no comparison to draw.
15 of the studies in Neoplasms, Germ Cell and Embryonal with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03067181Phase 3Children's Oncology GroupActive Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | 2027-06-30 |
| NCT03158064Memorial Sloan Kettering Cancer CenterEvaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | 2026-11 |
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT04308330New York Medical CollegeVorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | 2026-12-31 |
| NCT04435756SWOG Cancer Research NetworkA Study of miRNA 371 in Patients With Germ Cell Tumors | 2027-01-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.
This is a specimen collection study where patients with high-risk stage I germ cell tumor, clinical stage II germ cell tumor, and clinical stage III germ cell tumor will be evaluated for ctDNA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma.
Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 subjects will be enrolled with high-risk stage I seminomatous or non-seminomatous germ cell tumors. In these patients, ctDNA will be collected post-orchiectomy prior to initiation of surveillance and every 4 months during surveillance for up to 2 years.
Diagnostic Test: Whole blood for ctDNA
30 patients will be enrolled with clinical Stage II seminomatous or non-seminomatous germ cell tumor who are planning to undergo primary resection with RPLND. In these patients, ctDNA will be collected prior to surgery and every 4 months after surgery for up to 2 years.
Diagnostic Test: Whole blood for ctDNA
50 patients will be enrolled with clinical Stage III (or IS) seminomatous or non-seminomatous germ cell tumor who are planning to undergo first-line chemotherapy. In these patients, ctDNA will be collected prior to chemotherapy, at cycle 2 day 1, within 28 days of starting last cycle of chemotherapy, and every 4 months after completing chemotherapy.
Diagnostic Test: Whole blood for ctDNA
Whole blood for ctDNA
Positive predictive value (PPV) of circulating tumor DNA in Cohort I
PPV will be calculated as the number of true positives divided by the total number of positive tests in patients with high-risk stage I germ cell tumor.
Time frame: At screening and every 4 months up to 2 years
Positive predictive value (PPV) of circulating tumor DNA in Cohort II
PPV will be calculated as the number of true positives divided by the total number of positive tests in the node dissection patients with clinical stage II germ cell tumor.
Time frame: At screening and every 4 months up to 2 years
Positive predictive value (PPV) of circulating tumor DNA in Cohort III
PPV will be calculated as the number of true positives divided by the total number of positive tests in the first-line chemotherapy patients with clinical stage III germ cell tumor.
Time frame: At screening and every 4 months up to 2 years
Negative predictive value (NPV) of circulating tumor DNA in Cohort I
NPV will be calculated as the number of true negatives divided by the total number of negative tests in patients with high-risk stage I germ cell tumor.
Time frame: At screening and every 4 months up to 2 years
Negative predictive value (NPV) of circulating tumor DNA in Cohort II
NPV will be calculated as the number of true negatives divided by the total number of negative tests in the node dissection patients with clinical stage II germ cell tumor.
Time frame: At screening and every 4 months up to 2 years
Negative predictive value (NPV) of circulating tumor DNA in Cohort III
NPV will be calculated as the number of true positives divided by the total number of positive tests in the first-line chemotherapy patients with clinical stage III germ cell tumor.
Time frame: At screening and every 4 months up to 2 years
Post-node dissection circulating tumor DNA bioassay
Means/stds of ctDNA in both the relapsed and non-relapsed patients in Cohort II.
Time frame: At screening and every 4 months up to 2 years
Post-node dissection clearance rate of ctDNA
The clearance rate of ctDNA in the node dissection patients in Cohort II.
Time frame: At screening and every 4 months up to 2 years
Started Jun 2026 (actual). Primary completion is estimated for Dec 2032, 78 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplasms, Germ Cell and Embryonal →